<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EDETATE CALCIUM DISODIUM</span><br/>(ed'e-tate)<br/><span class="topboxtradename">Calcium Disodium Versenate, </span><span class="topboxtradename">Calcium EDTA<br/></span><b>Classifications:</b> <span class="classification">chelating agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Chelating agent that combines with divalent and trivalent metals to form stable, nonionizing soluble complexes that can be
         readily excreted by kidneys. Action is dependent on ability of heavy metal to displace the less strongly bound calcium in
         the drug molecule.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Chelating agent that binds with heavy metals such as lead to form a soluble complex which can be excreted through the kidney,
         thereby ridding the body of the poisonous substance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Principally as adjunct in treatment of acute and chronic lead poisoning (plumbism). Generally used in combination with dimercaprol
         (BAL) in treatment of lead encephalopathy or when blood lead level exceeds 100 mcg/dL. Also used to diagnose suspected lead
         poisoning.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of poisoning from other heavy metals such as chromium, manganese, nickel, zinc, and possibly vanadium; removal of
         radioactive and nuclear fission products such as plutonium, yttrium, uranium. Not effective in poisoning from arsenic, gold,
         or mercury.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe kidney disease, anuria; IV use in patients with lead encephalopathy not generally recommended (because of possible
         increase in intracranial pressure); pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney dysfunction; active tubercular lesions; history of gout; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diagnosis of Lead Poisoning</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 500 mg/m<sup>2</sup> (max: 1 g) over 1 h, then collect urine for 24 h (if mcg lead:mg EDTA ratio in urine is &gt;1, the test is positive)<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 50 mg/kg (max: 1 g), then collect urine for 68 h, (if mcg lead:mg EDTA ratio in urine is &gt;0.5, the test is positive)<br/><br/><span class="indicationtitle">Treatment of Lead Poisoning</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 11.5 g/m<sup>2</sup>/d infused over 824 h for up to 5 d <span class="rdroute">IM</span> 11.5 g/m<sup>2</sup>/d divided q812 h<br/><br/><span class="indicationtitle">Lead Nephropathy/Renal Impairment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Serum creatinine 2/d, 23 mg/dL  500 mg/m<sup>2</sup>/d, 3.14 mg/dL 400 mg/m<sup>2</sup> q48h, &gt;4 mg/dL 500 mg/m<sup>2</sup> once/wk. Infuse over 824 h for 5 d, may repeat monthly until lead excretion is reduced toward normal<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Calcium disodium edetate can produce potentially fatal effects when higher than recommended doses are used or when it is continued
            after toxic effects appear.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>IM route preferred for symptomatic children and recommended for patients with incipient or overt lead-induced encephalopathy.</li>
<li>Add Procaine HCl to minimize pain at injection site (usually 1 mL of procaine 1% to each 1 mL of concentrated drug). Consult
            physician.
         </li>
<li>Use separate injection sites when dimercaprol (BAL) and Calcium EDTA are given concurrently.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute the 5 mL ampule with 250500 mL of NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Warning: Rapid IV infusion may be <small>
<b>lethal</b>
</small> by suddenly increasing intracranial pressure in patients who already have cerebral edema. Manufacturer recommends total daily
                  dose over 812 h. Some clinicians recommend infusing over 12 h. Consult physician for specific rate.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Amphotericin B,</b>
<b>hydralazine,</b>
<b>Ringer's lactate.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Hypotension, thrombophlebitis. <span class="typehead"> GI:</span> Anorexia, nausea, vomiting, diarrhea, abdominal cramps, cheilosis. <span class="typehead">Hematologic:</span> Transient bone marrow depression, depletion of blood metals. <span class="typehead">Urogenital:</span>
<span class="speceff-life">Nephrotoxicity</span> (renal tubular necrosis), proteinuria, hematuria. <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Febrile reaction</span> (excessive thirst, fever, chills, severe myalgia, arthralgia, GI distress), <span class="speceff-common">histamine-like reactions</span> (flushing, throbbing headache, sweating, sneezing, nasal congestion, lacrimation, postural hypotension, tachycardia). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Edetate calcium disodium may decrease <span class="alt">serum cholesterol,</span>
<span class="alt">plasma lipid</span> levels (if elevated), and <span class="alt">serum potassium</span> values. <span class="alt">Glycosuria</span> may occur with toxic doses.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed IM. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> Peak chelation 2448 h. <span class="typehead">Distribution:</span> Distributed to extracellular fluid; does not enter CSF. <span class="typehead"> Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Chelated lead excreted in urine; 50% excreted in 1 h. <span class="typehead">Half-Life:</span> 2060 min IV, 90 min IM. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine adequacy of urinary output prior to therapy. This may be done by administering IV fluids before giving first dose.</li>
<li>Increase fluid intake to enhance urinary excretion of chelates. Avoid excess fluid intake, however, in patients with lead
            encephalopathy because of the danger of further increasing intracranial pressure. Consult physician regarding allowable intake.
         </li>
<li>Monitor I&amp;O. Since drug is excreted almost exclusively via kidneys, toxicity may develop if output is inadequate. Stop therapy
            if urine flow is markedly diminished or absent. Report any change in output or I&amp;O ratio to physician.
         </li>
<li>Lab tests: Obtain serum creatinine, calcium, and phosphorus before and during each course of therapy. Monitor baseline and
            frequent BUN levels and ECG during therapy. With prolonged therapy determine periodic determinations of blood trace element
            metals (e.g., copper, zinc, magnesium).
         </li>
<li>Be alert for occurrence of febrile reaction that may appear 48 h after drug infusion (see <small>ADVERSE EFFECTS</small>).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>